Immunofan (Arginyl-Alpha-Aspartyl-Lysyl-Valyl-Tyrosyl-Arginine)

1. Overview

Immunofan (also transliterated as Imunofan) is a synthetic hexapeptide immunomodulator with the structural formula arginyl-alpha-aspartyl-lysyl-valyl-tyrosyl-arginine and a molecular weight of 836 Da [1]. It was developed at the Central Research Institute of Epidemiology (CRIE) of the Ministry of Health of Russia, primarily by V.V. Lebedev and colleagues, as a modified synthetic analog of the biologically active region of thymopoietin -- a 49-amino acid peptide hormone secreted by thymic epithelial cells that regulates T-lymphocyte differentiation and immune system maturation [2][3][9].

Thymopoietin was first isolated from bovine thymus by Gideon Goldstein in 1974 [2]. The biologically active region was subsequently identified as the pentapeptide fragment at positions 32-36 (Arg-Lys-Asp-Val-Tyr), which was synthesized as the peptide thymopentin (TP-5) and shown to reproduce the immunomodulatory activity of the full-length molecule [3]. Immunofan represents a further modification of this thymopoietin-derived sequence, with structural optimization to enhance stability, duration of action, and pharmacological profile [1][7].

Immunofan was approved for clinical use in Russia in the 1990s and has accumulated over two decades of clinical experience in Russian medicine. It is registered for the treatment of immunodeficiency states, as adjuvant therapy in chronic infections (including hepatitis B and C, brucellosis, and opportunistic infections), and as supportive therapy in oncology to reduce immunosuppressive effects of chemotherapy and radiation [1][13]. The drug is available in three pharmaceutical forms: injectable solution (45 mcg/mL for intramuscular or subcutaneous injection), intranasal spray (50 mcg per dose), and rectal suppositories (90-100 mcg per suppository) [1].

Outside of Russia and the Commonwealth of Independent States (CIS), Immunofan has not received regulatory approval from any Western agency including the FDA, EMA, or MHRA. The evidence base is predominantly from Russian-language literature, with limited representation in Western peer-reviewed journals, making independent assessment challenging [1].

Molecular Weight

836 Da

Sequence

Arg-alpha-Asp-Lys-Val-Tyr-Arg

Parent Molecule

Thymopoietin (modified fragment of residues 32-36)

Developer

Central Research Institute of Epidemiology, Moscow

Available Forms

Injectable (45 mcg/mL), intranasal spray (50 mcg/dose), rectal suppositories (90-100 mcg)

Russian Approval

Approved for immunodeficiency states, chronic infections, oncology adjunct

FDA/EMA Status

Not approved outside Russia and CIS countries

Duration of Action

Three phases: fast (2-3 hours), medium (7-10 days), slow (up to 4 months)

Veterinary Use

Also approved in Russia for veterinary immunomodulation

2. Mechanism of Action

Immunofan's pharmacological action is characterized by a distinctive three-phase temporal profile, with each phase engaging different aspects of the immune and antioxidant systems [1][7][8].

Phase 1: Fast Phase (2-3 Hours Post-Administration)

The immediate effects of Immunofan begin within 2-3 hours of administration and involve:

• Ceruloplasmin regulation: Immunofan modulates ceruloplasmin levels, a copper-containing ferroxidase that functions as a major plasma antioxidant. This represents the immediate antioxidant protective mechanism.
• Free radical inactivation: The peptide directly promotes inactivation of reactive oxygen species (ROS) and lipid peroxidation products, reducing oxidative stress in tissues.
• Detoxification enhancement: Hepatoprotective effects manifest rapidly through restoration of cellular detoxification pathways [1][7].

Phase 2: Medium Phase (7-10 Days)

Over the first 7-10 days, Immunofan produces:

• Enhanced phagocytosis: Neutrophil and macrophage bactericidal activity is augmented through restoration of the oxygen-dependent killing system.
• Improved bacterial killing: The peptide enhances the intracellular destruction of pathogens by phagocytic cells.
• Antibody production stimulation: Humoral immunity is supported through enhanced B-cell differentiation and immunoglobulin synthesis [1][8].

Phase 3: Slow Phase (Up to 4 Months)

The prolonged immunomodulatory effects include:

• T-cell subset normalization: CD4+/CD8+ ratios are restored toward normal values in immunodeficient patients.
• Cellular immunity restoration: T-cell proliferative responses and cytokine production are normalized.
• Immune memory enhancement: Long-term improvements in immune surveillance and response capacity persist for up to 4 months after a treatment course [1][7][13].

Immunomodulatory vs. Immunostimulatory

A key distinction of Immunofan is its modulatory rather than simply stimulatory mechanism. The peptide returns abnormal immune parameters toward reference values regardless of the direction of the abnormality -- it increases depressed indicators while reducing elevated ones [1]. This bidirectional regulation provides safety advantages over non-specific immune stimulants and ensures balanced immune restoration rather than potentially harmful immune hyperactivation.

Multidrug Resistance Reversal

Immunofan has been shown to inhibit the multidrug resistance (MDR) mechanism mediated by transmembrane transport pump proteins (P-glycoprotein family) [18]. This effect has clinical implications in two settings:

• Oncology: Overcoming tumor cell resistance to chemotherapeutic agents
• Steroid resistance: Restoring sensitivity to glucocorticoid therapy in steroid-resistant conditions [18]

Hepatoprotective Mechanism

The hepatoprotective effects of Immunofan are attributed to:

• Restoration of oxidative-antioxidant balance in hepatocytes
• Enhancement of liver detoxification enzyme activity
• Reduction of inflammatory cytokine levels in liver tissue
• Improved hepatic microcirculation [1][12]

3. Researched Applications

Immunodeficiency States (Approved in Russia)

Evidence level: Limited clinical (Russian approval with extensive clinical use)

Immunofan is approved in Russia for secondary immunodeficiency states characterized by depressed cellular immunity, reduced phagocytic function, and increased susceptibility to infections [1][13]. Clinical experience spanning over two decades has documented restoration of T-cell counts, normalization of CD4/CD8 ratios, and enhancement of phagocytic bacterial killing capacity in immunodeficient patients.

Chronic Viral Hepatitis (Approved in Russia)

Evidence level: Limited clinical (Russian clinical studies)

Immunofan has been studied and approved as adjunct therapy in chronic hepatitis B and C [12]. In hepatitis B patients, treatment was associated with stimulation of antiviral immunity, inhibition of viral replication, seroconversion of HBs and HBe antigens, and normalization of immune parameters. In hepatitis C patients, Immunofan reduced liver inflammatory activity, improved microcirculation, and augmented anti-HCV antibody production [12].

Oncology Adjuvant Therapy (Approved in Russia)

Evidence level: Limited clinical (Russian clinical studies)

Immunofan is used in Russian oncology practice to counteract the immunosuppressive effects of chemotherapy and radiation therapy [1][13]. Clinical experience has documented reduced infectious complications, improved T-cell recovery after cytotoxic therapy, and potential enhancement of anti-tumor immune responses through restoration of natural killer cell activity and T-cell function.

Chronic Bacterial Infections (Approved in Russia)

Evidence level: Limited clinical (Russian clinical studies)

In complex therapy for chronic infections including brucellosis and other intracellular pathogens, Immunofan has been shown to enhance antibacterial immunity, shorten clinical symptom duration, and reduce recurrence rates [1].

Allergic Diseases

Evidence level: Preliminary (Russian clinical studies)

Immunofan's immunomodulatory mechanism includes normalization of the Th1/Th2 balance, which is disrupted in allergic diseases. Clinical studies in patients with allergic rhinitis and bronchial asthma have reported reduced IgE levels and improved clinical symptoms [1].

Perioperative Immunoprotection

Evidence level: Preliminary (Russian clinical studies)

Perioperative administration of Immunofan has been studied for reducing postoperative infectious complications in patients undergoing major surgery, with reported decreases in infection rates and shortened hospital stays [13].

Veterinary Applications (Approved in Russia)

Evidence level: Limited clinical (veterinary approval)

Immunofan is also approved for veterinary use in Russia for immunomodulation in companion and farm animals, including treatment of viral infections such as canine parvovirus.

4. Clinical Evidence Summary

The evidence base for Immunofan has important limitations that must be acknowledged:

1. Predominantly Russian-language literature: The vast majority of clinical studies are published in Russian journals not indexed in major Western databases.
2. Limited independent replication: Most studies originate from the developer's research group or affiliated institutions.
3. Study design quality: Published studies often lack rigorous randomization, blinding, and statistical methodology by Western clinical trial standards.
4. No Western regulatory review: The evidence has not undergone the scrutiny of FDA, EMA, or similar Western regulatory assessment.
5. Single PubMed-indexed review: The most accessible English-language reference is the 1999 review by Pokrovsky et al. [1].

Despite these limitations, Immunofan has accumulated substantial real-world clinical experience in Russia over more than 20 years, with consistent reports of immunomodulatory efficacy and favorable safety profiles across multiple indications [1][13].

5. Dosing in Research

The following dosing protocols reflect approved Russian clinical guidelines. These are not recommendations for use outside of regulated medical practice.

Key dosing observations:

• Standard treatment courses consist of 8-10 injections administered every other day (alternate-day dosing) [1].
• The three-phase duration of action (up to 4 months for the slow phase) means that therapeutic effects persist well beyond the active treatment period.
• Multiple routes of administration (injection, intranasal, rectal) provide flexibility based on clinical setting and patient preference.
• Repeat courses may be administered after intervals determined by clinical response and immune monitoring.
• The intranasal route offers non-invasive administration particularly suitable for pediatric and outpatient settings.

6. Safety and Side Effects

Reported Safety Profile

Immunofan has been characterized in Russian clinical literature as having a favorable safety profile across the approved indications [1][13]:

• No immunological overstimulation: The modulatory mechanism ensures that immune parameters are normalized toward reference values rather than pushed to potentially harmful extremes.
• No reported autoimmune exacerbation: Unlike non-specific immunostimulants, Immunofan has not been reported to trigger or worsen autoimmune conditions, attributed to its balanced Th1/Th2 modulation.
• Minimal injection site reactions: Local reactions with intramuscular or subcutaneous injection are described as rare and mild.
• No significant systemic toxicity: No serious adverse events attributable to Immunofan have been reported in published Russian clinical literature spanning over 20 years of use.

Contraindications (per Russian labeling)

• Hypersensitivity to the active substance or excipients
• Pregnancy with Rh-factor conflict (specific to injectable form)
• Children under 2 years of age (for certain formulations)

Precautions

• Drug interactions: Immunofan's ability to reverse multidrug resistance may theoretically alter the pharmacokinetics of co-administered drugs eliminated by P-glycoprotein-mediated transport [18].
• Autoimmune conditions: While no exacerbation has been reported, immunomodulatory agents should be used with caution in patients with autoimmune diseases.
• Limited Western safety data: The safety profile has not been independently assessed by Western regulatory agencies, and rare adverse effects may not have been captured in the available Russian literature.
• Pregnancy and lactation: Use during pregnancy is contraindicated per Russian labeling (particularly with Rh-factor conflict). Data during lactation are limited.

Comparison with Related Thymic Peptides

| Compound | Origin | Mechanism | Russian Approval | Western Approval | |---|---|---|---|---| | Immunofan | Synthetic (thymopoietin analog) | Immunomodulatory, antioxidant, hepatoprotective | Yes | No | | Thymalin | Bovine thymus extract | Immunomodulatory (polypeptide complex) | Yes | No | | Thymogen (L-Glu-L-Trp) | Synthetic (thymalin-derived dipeptide) | Immunomodulatory | Yes | No | | Thymosin Alpha-1 (Zadaxin) | Synthetic (thymosin alpha-1) | Immunostimulatory | No (discontinued globally) | Orphan drug status (limited) |

7. Regulatory Status

Russia: Immunofan is a registered pharmaceutical approved by the Russian Ministry of Health for clinical use across multiple indications including immunodeficiency, chronic infections, and oncology adjunct therapy. It is produced by NPP Bionox (Scientific and Production Enterprise Bionox), Moscow [1][13].

CIS Countries: Available in several Commonwealth of Independent States countries under Russian pharmaceutical registration.

FDA (United States): Not approved and not under investigation. No IND filing or clinical trial registration exists on ClinicalTrials.gov.

EMA (European Union): Not approved and not under investigation.

Veterinary: Approved in Russia for veterinary immunomodulation.

International availability: Immunofan is available for purchase from Russian pharmaceutical export services, but its import into Western countries may be subject to pharmaceutical importation regulations.

8. Pharmacokinetics

Immunofan's pharmacokinetics are best understood through its distinctive three-phase pharmacodynamic model rather than classical drug concentration-time curves, as detailed pharmacokinetic studies measuring plasma peptide levels have not been published in English-language literature [1][7][8].

Three-phase mechanism as pharmacokinetic framework. Rather than conventional absorption-distribution-metabolism-elimination parameters, Immunofan's clinical behavior is characterized by three sequential phases of biological activity that unfold over very different timescales [1][7]:

• Fast phase (2-3 hours): Immediate antioxidant effects including ceruloplasmin regulation, free radical inactivation, and hepatoprotective action. This rapid onset is consistent with a short plasma half-life (probably minutes to hours for the hexapeptide itself) and rapid receptor engagement and signaling initiation.
• Medium phase (7-10 days): Enhanced phagocytosis, improved bacterial killing, and antibody production stimulation. This sustained phase far exceeds the likely plasma persistence of the peptide, indicating that Immunofan triggers cellular reprogramming events (gene expression changes, immune cell differentiation) that persist after the peptide is cleared.
• Slow phase (up to 4 months): T-cell subset normalization, cellular immunity restoration, and immune memory enhancement. This extraordinarily prolonged effect is attributable to immunological memory mechanisms -- changes in T-cell populations, cytokine production capacity, and immune surveillance that constitute lasting biological reprogramming rather than ongoing drug exposure.

Route-dependent bioavailability. Immunofan is available in three formulations, each with different pharmacokinetic profiles [1]:

• Intramuscular/subcutaneous injection (45 mcg): The injectable route provides the most reliable systemic bioavailability and is the most extensively studied formulation. The every-other-day dosing schedule (8-10 injections per course) aligns with the medium-phase pharmacodynamics, allowing each dose to reinforce the developing immune response.
• Intranasal spray (50 mcg): The intranasal route provides non-invasive administration with absorption through the nasal mucosa. Bioavailability relative to injection has not been formally determined, but clinical efficacy has been documented for this route.
• Rectal suppositories (90-100 mcg): The higher dose reflects anticipated lower bioavailability via rectal absorption compared to parenteral administration. Rectal delivery avoids hepatic first-pass metabolism.

Metabolism and clearance. As a synthetic hexapeptide (836 Da), Immunofan is expected to undergo rapid proteolytic degradation by plasma and tissue peptidases, with metabolic fragments cleared renally. The lack of hepatic CYP450 involvement minimizes drug-drug interaction potential through metabolic pathways, though the P-glycoprotein modulation (multidrug resistance reversal) could theoretically affect the pharmacokinetics of co-administered substrates [18].

Duration of therapeutic effect. The recommended treatment course of 8-10 injections over 16-20 days (every other day) is followed by therapeutic effects persisting for up to 4 months, giving Immunofan one of the most favorable dosing-to-effect ratios among immunomodulatory peptides. This extended duration means that repeat courses are typically administered at 3-4 month intervals based on clinical monitoring of immune parameters.

9. Dose-Response Relationships

Immunofan dose-response data derive primarily from Russian clinical protocols rather than formal dose-ranging studies conducted to Western standards [1][7][13].

Standard dosing across indications. A notable feature of Immunofan's clinical use is the relatively uniform dose across different indications: 45 mcg per administration for both adults and older children, regardless of whether the target is immunodeficiency, chronic infection, or oncology adjunct therapy [1]. This dose uniformity across indications suggests either that the effective dose was established empirically and applied broadly, or that the immunomodulatory mechanism operates as a binary switch (on/off) at the standard dose rather than producing graded dose-dependent effects.

Route-dependent dose adjustment. The dose varies by route: 45 mcg for injection, 50 mcg for intranasal spray, and 90-100 mcg for rectal suppositories [1]. These dose adjustments reflect anticipated differences in bioavailability rather than pharmacodynamic dose-response relationships.

Course duration dose-response. The clinical response appears to correlate with the number of administrations in a course rather than individual dose magnitude. Standard courses of 8-10 injections produce measurable immunological normalization, while shorter courses may produce incomplete immune restoration. Extended courses (15 injections) are used in oncology adjunct protocols where more profound immunosuppression requires longer treatment [1][13].

Immunological parameter normalization. The immunomodulatory effect is bidirectional: Immunofan restores depressed immune parameters toward normal reference values while reducing elevated parameters toward the same targets [1]. This modulatory dose-response pattern differs from conventional stimulatory agents, where higher doses produce proportionally greater immune activation. The clinical implication is that standard dosing is appropriate regardless of the degree of immune abnormality, as the mechanism inherently self-regulates toward homeostasis.

Pediatric dosing. Children receive the same 45 mcg per administration as adults, though the every-other-day schedule and total number of administrations may be adjusted based on the clinical indication and the child's immune monitoring results [1].

10. Comparative Effectiveness

Immunofan vs. Thymosin Alpha-1 (Zadaxin)

Thymosin alpha-1 (Ta1) is a 28-amino acid peptide originally isolated from thymic tissue by Allan Goldstein in 1977 [15]. While both are thymus-derived immunomodulatory peptides, their mechanisms, clinical development paths, and evidence quality differ substantially. Thymosin alpha-1 primarily stimulates immune function through dendritic cell maturation, Th1 polarization, and cytotoxic T-cell activation, acting as an immunostimulant rather than an immunomodulator [15]. Immunofan's bidirectional modulatory mechanism (normalizing both depressed and elevated parameters) provides a theoretical safety advantage over unidirectional stimulation. Thymosin alpha-1 had limited international approval (as Zadaxin in some countries, primarily for hepatitis B and C), but was never FDA-approved and was discontinued globally. Both have been used as oncology adjuncts and in chronic viral hepatitis, but thymosin alpha-1 has a more extensive English-language literature and has been evaluated in studies meeting Western clinical trial standards.

Immunofan vs. Thymogen (L-Glu-L-Trp)

Thymogen is a synthetic dipeptide (glutamyl-tryptophan) derived from the active sequence of thymalin, approved in Russia alongside Immunofan as a thymic peptide immunomodulator. In a comparative clinical study, Immunofan demonstrated broader immunomodulatory activity than Thymogen, with additional antioxidant and hepatoprotective effects not shared by the simpler dipeptide [1]. Thymogen's mechanism is more narrowly focused on T-cell stimulation, while Immunofan's three-phase action provides antioxidant protection (fast phase), enhanced phagocytosis (medium phase), and sustained immune reconstitution (slow phase). For clinical scenarios requiring hepatoprotection (chronic hepatitis) or antioxidant support (oxidative stress conditions), Immunofan offers advantages over Thymogen.

Immunofan vs. Thymalin

Thymalin is a polypeptide complex extracted from bovine thymus containing multiple peptide components, including the dipeptide L-Glu-L-Trp [5][6]. Unlike Immunofan (a defined single synthetic hexapeptide), Thymalin is a natural extract with variable composition between batches. Immunofan's defined structure provides reproducibility advantages. Thymalin has been studied extensively by the Khavinson group for geroprotective effects, with claimed life extension in animal models and long-term human studies [5][6]. Immunofan lacks comparable longevity data but has more specific clinical indication data across immunodeficiency, infection, and oncology settings.

Limitations of Comparative Assessment

All comparisons between Immunofan and other thymic peptides must be interpreted with caution due to the predominantly Russian-language evidence base, limited independent replication, and absence of Western regulatory review for any of these agents. Head-to-head comparisons typically come from single-center Russian studies without the rigorous randomization, blinding, and statistical methodology expected in Western clinical trials.

| Feature | Immunofan | Thymosin Alpha-1 | Thymogen | Thymalin | |---|---|---|---|---| | Structure | Synthetic hexapeptide | 28-amino acid peptide | Synthetic dipeptide | Bovine thymus extract | | Mechanism | Immunomodulatory (bidirectional) | Immunostimulatory | T-cell stimulatory | Immunomodulatory | | Antioxidant activity | Yes (fast phase) | Limited | No | Some | | Hepatoprotective | Yes | Limited | No | Not documented | | Duration of effect | Up to 4 months | Weeks | Weeks | Weeks | | Western evidence | Very limited | Moderate | Minimal | Minimal | | Russian approval | Yes | No | Yes | Yes |

11. Enhanced Safety Profile

Immunofan's safety profile is characterized in Russian clinical literature as exceptionally favorable, though this assessment must be tempered by the limitations of the evidence base [1][13].

Modulatory vs. stimulatory safety advantage. The fundamental safety advantage of Immunofan over non-specific immunostimulants lies in its bidirectional modulatory mechanism [1]. Rather than pushing immune parameters in a single direction (which can cause immunological overshoot, autoimmune flares, or cytokine storm), Immunofan normalizes abnormal values toward physiological reference ranges regardless of whether they are elevated or depressed. This self-correcting property provides an inherent safety buffer against immune hyperactivation.

No reported autoimmune exacerbation. In over two decades of Russian clinical use, Immunofan has not been reported to trigger or worsen autoimmune conditions [1][13]. This contrasts with some immunostimulatory agents (interferons, thymosin alpha-1 at high doses) that have been associated with autoimmune flares. The Th1/Th2 balancing mechanism may contribute to this safety profile by preventing excessive polarization in either direction.

Minimal injection site reactions. Local reactions with intramuscular or subcutaneous injection are described as rare and mild [1]. The low injection volume (1 mL) and the peptide's small molecular weight contribute to good local tolerability.

Long-term safety. Russian clinical experience spanning more than 20 years with Immunofan has not identified delayed or cumulative toxicity [13]. The fact that the peptide's duration of action (up to 4 months) far exceeds its plasma persistence suggests that long-term effects are mediated by immunological reprogramming rather than ongoing drug exposure, reducing the risk of cumulative toxicity.

Pregnancy contraindication. Immunofan is contraindicated in pregnancy with Rh-factor conflict per Russian labeling, though the specific mechanism of concern has not been detailed in available literature [1]. General pregnancy safety data are absent.

Drug interactions. The P-glycoprotein modulation (multidrug resistance reversal) documented for Immunofan represents a potentially clinically significant drug interaction mechanism [18]. Co-administered drugs that are P-glycoprotein substrates (certain chemotherapeutics, immunosuppressants, cardiac glycosides) may have altered pharmacokinetics. This effect is therapeutic in the oncology setting (overcoming tumor drug resistance) but requires awareness in polypharmacy situations.

Pediatric safety. Immunofan has been used in children (above age 2 per Russian labeling) for recurrent respiratory infections and secondary immunodeficiency, with reported normalization of T-cell counts and improved phagocytic function without serious adverse events [1]. Intranasal administration provides a non-invasive option particularly suitable for pediatric use.

Veterinary safety. Russian veterinary approval and clinical use in companion animals (dogs, cats) for conditions including canine parvovirus provides additional cross-species safety data supporting the favorable tolerability profile.

Evidence limitations. The safety characterization must be qualified by the same limitations affecting the entire Immunofan evidence base: predominantly Russian-language literature, limited independent replication, absence of rigorous pharmacovigilance systems, and no Western regulatory safety review [1][13].

12. Related Peptides

See also: Thymalin, Thymosin Alpha-1, Epithalon, Selank, Semax

• Thymalin -- A polypeptide complex extracted from bovine thymus containing the dipeptide L-Glu-L-Trp (EW), approved in Russia since the 1980s. Unlike Immunofan (a single synthetic hexapeptide), Thymalin is a natural extract containing multiple peptide components.

• Thymosin Alpha-1 -- A 28-amino acid thymic peptide with immunostimulatory properties. Unlike Immunofan's modulatory mechanism, thymosin alpha-1 primarily stimulates immune function. It had limited international approval (as Zadaxin) before discontinuation.

• Epithalon -- A synthetic tetrapeptide (Ala-Glu-Asp-Gly) based on the pineal peptide epithalamin, developed by the Khavinson group at the St. Petersburg Institute of Bioregulation and Gerontology. Like Immunofan, it represents the Russian school of peptide bioregulation.

• Selank -- A synthetic heptapeptide based on the natural immunomodulatory peptide tuftsin, developed at the Institute of Molecular Genetics in Moscow. Approved in Russia primarily as an anxiolytic but shares the immunomodulatory peptide development tradition with Immunofan.

• Semax -- A synthetic ACTH analog heptapeptide developed in Russia with nootropic and neuroprotective properties. Another example of the Russian synthetic peptide pharmaceutical tradition from which Immunofan emerged.

13. References

1. [1] Pokrovsky VI, Pokrovsky VV, Lebedev VV. (1999). Imunofan: new-generation synthetic peptide agent. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk. PubMed
2. [2] Goldstein G. (1974). Isolation of bovine thymin: a polypeptide hormone of the thymus. Nature. DOI PubMed
3. [3] Goldstein G, Scheid MP, Boyse EA, Schlesinger DH, Van Wauwe J. (1979). A synthetic pentapeptide with biological activity characteristic of the thymic hormone thymopoietin. Science. DOI PubMed
4. [4] Schlesinger DH, Goldstein G, Niall HD. (1975). The complete amino acid sequence of ubiquitin, an adenylate cyclase stimulating polypeptide probably universal in living cells. Biochemistry. DOI PubMed
5. [5] Khavinson VKh, Morozov VG. (2003). Peptides of pineal gland and thymus prolong human life. Neuroendocrinology Letters. PubMed
6. [6] Khavinson VKh, Morozov VG, Malinin VV, Kazakova TB, Korneva EA. (2002). Geroprotective effect of thymalin and epithalamin. Advances in Gerontology. PubMed
7. [7] Lebedev VV. (1999). Immunofan -- a synthetic peptide drug: mechanisms of action and clinical applications. Immunologiya.
8. [8] Lebedev VV, Pokrovsky VI. (2001). Immunofan: regulation of immune and oxidative-antioxidant processes in clinical practice. Russian Journal of Immunology.
9. [9] Goldstein G. (1980). Thymopoietin and the immune system. Immunology Today.
10. [10] Audhya T, Scheid MP, Goldstein G. (1984). Contrasting biological activities of thymopoietin and splenin, two closely related polypeptide products of thymus and spleen. Proceedings of the National Academy of Sciences. DOI PubMed
11. [11] Khavinson VKh, Malinin VV. (2005). Gerontological aspects of genome peptide regulation. Karger.
12. [12] Lebedev VV, Stepanov OG, Pokrovsky VI. (2002). The role of Immunofan in the complex therapy of patients with chronic viral hepatitis B and C. Epidemiologiya i Infektsionnye Bolezni.
13. [13] Pokrovsky VI, Lebedev VV, Shelepin AA. (2010). Immunofan: 15 years of clinical experience. Russian Journal of Immunology.
14. [14] Bach JF. (1979). Thymic hormones. Journal of Immunopharmacology. PubMed
15. [15] Goldstein AL, Low TL, McAdoo M, McClure J, Thurman GB, Rossio JL, et al. (1977). Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide. Proceedings of the National Academy of Sciences. DOI PubMed
16. [16] Anisimov VN, Khavinson VKh. (2010). Peptide bioregulation of aging: results and prospects. Biogerontology. DOI PubMed
17. [17] Khavinson VKh. (2002). Peptides and ageing. Neuroendocrinology Letters. PubMed
18. [18] Lebedev VV. (2009). Immunofan: mechanisms and methods for the study of immunocorrecting, antimutagenic, anti-inflammatory, and hepatoprotective activities. Russian patent documentation and clinical monographs.